Results 91 to 100 of about 512,272 (346)

UFO Presents! A viral hepatitis prevention and education program for young adult IDUs [PDF]

open access: yes, 2009
UFO Presents! is a Center for Disease Control and Prevention (CDC)-funded program providing much needed hepatitis education, prevention and care services for youth and young adults with injection risk in San Francisco, CA.

core  

Multiple effects of silymarin on the hepatitis C virus lifecycle [PDF]

open access: yes, 2010
Silymarin, an extract from milk thistle (Silybum marianum), and its purified flavonolignans have been recently shown to inhibit hepatitis C virus (HCV) infection, both in vitro and in vivo.
Bourne, Nigel   +16 more
core   +1 more source

Cleavage‐Resistant CYLD Protects Against Autoimmune Hepatitis

open access: yesAdvanced Science, EarlyView.
Proteolytic cleavage of the deubiquitinase CYLD emerges as a critical driver of autoimmune hepatitis. TNFα‐induced CYLD loss in macrophages amplifies S100A9‐triggered MAPK activation, leading to excessive chemokine production and hepatic inflammation. Pharmacological inhibition of MEK signaling effectively attenuates experimental disease, highlighting ...
Han Liu   +13 more
wiley   +1 more source

Apoptotic epitope-specific CD8+ T cells and interferon signaling intersect in chronic hepatitis C virus infection [PDF]

open access: yes, 2015
CD8(+) T cells specific to caspase-cleaved antigens derived from apoptotic T cells represent a principal player in chronic immune activation (CIA). Here, we found that both apoptotic epitope (AE)-specific and hepatitis C virus (HCV)-specific CD8(+) T ...
Accapezzato, Daniele   +18 more
core   +1 more source

Identification and Characterization of an In Silico Designed Membrane‐Active Peptide with Antiviral Properties

open access: yesAdvanced Science, EarlyView.
An evolutionary molecular dynamics platform is used to design P1.6, a membrane‐active peptide that senses lipid packing defects in viral envelopes. P1.6 adopts a stabilized α‐helical structure upon membrane contact, disrupts virus‐like liposomes, and damages HIV‐1 particles.
Pascal von Maltitz   +10 more
wiley   +1 more source

Biomarkers in Detection of Hepatitis C Virus Infection

open access: yesPathogens
The hepatitis C virus (HCV) infection affects 58 million people worldwide. In the United States, the incidence rate of acute hepatitis C has doubled since 2014; during 2021, this increased to 5% from 2020.
Jungreem Woo, Youkyung Choi
doaj   +1 more source

Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. [PDF]

open access: yes, 2008
Hepatitis C virus (HCV) infection is dependent on at least three coreceptors: CD81, scavenger receptor BI (SR-BI), and claudin-1. The mechanism of how these molecules coordinate HCV entry is unknown.
Balfe, Peter   +6 more
core   +3 more sources

A Deep Representation Learning Method for Quantitative Immune Defense Function Evaluation and Its Clinical Applications

open access: yesAdvanced Science, EarlyView.
ImmuDef, a novel algorithm to quantitatively evaluate the anti‐infection immune defense function of an individual based on RNA‐seq data via a variational autoencoder (VAE) model. It is validated on 3200+ samples across four immune states with high accuracy. It can serve as a metric for disease severity and prognosis across pathogenic cohorts.
Zhen‐Lin Tan   +7 more
wiley   +1 more source

Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

open access: yesHealth Science Reports, 2020
Background and Aims Direct‐acting antiviral therapy for hepatitis C virus (HCV) is effective, but few prospective studies among people with ongoing injecting drug use exist.
Jason Grebely   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy